[8-K] Century Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) furnished materials related to its latest quarter and pipeline. The company provided an earnings press release for the quarter ended September 30, 2025, and an updated investor presentation. It also announced its first Type 1 diabetes program, CNTY-813.

The earnings release (Exhibit 99.1), investor presentation (Exhibit 99.2), and CNTY-813 press release (Exhibit 99.3) were furnished on November 13, 2025 and are not deemed “filed” under the Exchange Act.

8-K Event Classification

4 items: 2.02, 7.01, 8.01, 9.01

4 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001850119 0001850119 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40498		84-2040295
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

25 North 38th Street, 11th Floor Philadelphia, Pennsylvania		19104
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share		IPSC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On November 13, 2025, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure

On November 13, 2025, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On November 13, 2025, the Company also issued a press release announcing its first program for Type 1 diabetes, CNTY-813. A copy of the press release is furnished herewith as Exhibit 99.3, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Document
99.1		Earnings Press Release of Century Therapeutics, Inc., dated November 13, 2025
99.2		Investor Presentation of Century Therapeutics, Inc., dated November 13, 2025
99.3		Press Release of Century Therapeutics, Inc., dated November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.
By:	/s/ Brent Pfeiffenberger, PharmD, MBA
Name:	Brent Pfeiffenberger, PharmD, MBA
Title:	President and Chief Executive Officer

Date: November 13, 2025

FAQ

What did Century Therapeutics (IPSC) disclose in this 8-K?

It furnished an earnings press release for the quarter ended September 30, 2025, an updated investor presentation, and a press release for CNTY-813.

Which exhibits were included with IPSC’s 8-K?

Exhibit 99.1 (earnings press release), Exhibit 99.2 (investor presentation), and Exhibit 99.3 (CNTY-813 program press release).

Is the information considered filed or furnished?

The information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, and the CNTY-813 release (99.3), is furnished and not deemed filed.

What period does the earnings press release cover for IPSC?

It covers the quarter ended September 30, 2025.

What new program did IPSC announce?

The company announced its first Type 1 diabetes program, CNTY-813.

What is IPSC’s trading symbol and exchange?

IPSC on the Nasdaq Capital Market.

Is Century Therapeutics an emerging growth company?

Yes, it is identified as an emerging growth company.